Kazia Therapeutics Limited KZIA
7.00 USD -1.08 (-13.37%)
At closeNov 6, 2026, 6:55 AM EST
6.91 -0.09 -1.29%
Pre-market · Nov 6, 6:55 AM ET
7.00 Day range 7.99
4.86 52-week range 17.40
- YTD
- +1.60%
- 1 year
- -8.85%
News
prnewswire.com Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an…
benzinga.com Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming ActivitySYDNEY, Nov. 2, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an
prnewswire.com Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"),…
benzinga.com This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).- benzinga.com Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27 Needham analyst Gil Blum initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $27.
benzinga.com This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiate coverage: Buy on AIR Global, Robinhood and Kazia; Outperform on Equinix; Neutral on Zscaler, with price targets.
benzinga.com Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35 Guggenheim analyst Paul Jeng initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $35.
benzinga.com Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30 Leerink Partners analyst Andrew Berens initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Outperform rating and announces Price Target of $30.